Cargando…

Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors

EGFR and VEGFR-2 represent promising targets for cancer treatment as they are very important in tumor development as well as in angiogenesis and metastasis. In this work, 6-amino-4-(2-bromophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile 1 and (E)-4-(2-Bromobenzylidene)-5-methyl-2,4-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saleh, Nashwa M., El-Gazzar, Marwa G., Aly, Hala M., Othman, Rana A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993756/ https://www.ncbi.nlm.nih.gov/pubmed/32039146 http://dx.doi.org/10.3389/fchem.2019.00917

Ejemplares similares

Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors
por: Sun, Shaofeng, et al.
Publicado: (2017)

In Vitro Anticancer Activity Screening of Novel Fused Thiophene Derivatives as VEGFR-2/AKT Dual Inhibitors and Apoptosis Inducers
por: Abdelnaby, Rana M., et al.
Publicado: (2022)

Pyrazole-sulfonamide scaffold featuring dual-tail strategy as apoptosis inducers in colon cancer
por: El-Hazek, Reham M. M., et al.
Publicado: (2023)

A New Series of Indeno[1,2-c]pyrazoles as EGFR TK Inhibitors for NSCLC Therapy
por: Özdemir, Ahmet, et al.
Publicado: (2022)

Synthesis and Anticancer Activities of Pyrazole–Thiadiazole-Based EGFR Inhibitors
por: Kurban, Berkant, et al.
Publicado: (2023)

The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization
por: Ihmaid, Saleh, et al.
Publicado: (2018)

Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile
por: Mghwary, Aml E.-S., et al.
Publicado: (2019)

Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact
por: El-Hazek, Reham M. M., et al.
Publicado: (2023)

Discovery of a series of novel phenylpiperazine derivatives as EGFR TK inhibitors
por: Sun, Juan, et al.
Publicado: (2015)

Novel 3-phenylquinazolin-2,4(1H,3H)-diones as dual VEGFR-2/c-Met-TK inhibitors: design, synthesis, and biological evaluation
por: Hassan, Abdelfattah, et al.
Publicado: (2023)

Design and biological evaluation of 3-substituted quinazoline-2,4(1H,3H)-dione derivatives as dual c-Met/VEGFR-2-TK inhibitors
por: Hassan, Abdelfattah, et al.
Publicado: (2023)

Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2
por: El-Sayed, Wael A., et al.
Publicado: (2022)

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer
por: Abdelsalam, Esraa A., et al.
Publicado: (2022)

Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2/EGFR(T790M) tyrosine kinase inhibitors
por: Aziz, Nada A. A. M., et al.
Publicado: (2022)

Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies
por: Altamimi, Abdulmalik S., et al.
Publicado: (2021)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
por: Fakhry, Mariam M., et al.
Publicado: (2023)

Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2
por: Sangande, Frangky, et al.
Publicado: (2020)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors
por: Shaldam, Moataz A., et al.
Publicado: (2023)

Synthesis, Biological Evaluation, and Molecular Modeling Studies of 1-Aryl-1H-pyrazole-Fused Curcumin Analogues as Anticancer Agents
por: Doan, Nam Q. H., et al.
Publicado: (2022)

Novel EGFR-TK Inhibitor EKB-569 Inhibits Hepatocellular Carcinoma Cell Proliferation by AKT and MAPK Pathways
por: Kim, Heesue, et al.
Publicado: (2011)

Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR(T790M) and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations
por: Anwer, Kurls E., et al.
Publicado: (2023)

Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists
por: Abdelgawad, Mohamed A., et al.
Publicado: (2022)

Design, synthesis, and docking studies of novel pyrazole-based scaffolds and their evaluation as VEGFR2 inhibitors in the treatment of prostate cancer
por: Soliman, Dalia H., et al.
Publicado: (2023)

Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies
por: Al-Muntaser, Samia M., et al.
Publicado: (2023)

The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
por: Nitulescu, George Mihai, et al.
Publicado: (2023)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

Synthesis, Characterisation, and In Vitro Anticancer Activity of Curcumin Analogues Bearing Pyrazole/Pyrimidine Ring Targeting EGFR Tyrosine Kinase
por: Ahsan, Mohamed Jawed, et al.
Publicado: (2013)

Tcl/Tk tools
por: Harrison, M, et al.
Publicado: (1997)

New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and in silico study
por: Al-Sanea, Mohammad M., et al.
Publicado: (2023)

Structural analysis of cannabinoids against EGFR-TK leads a novel target against EGFR-driven cell lines
por: Lamtha, Thomanai, et al.
Publicado: (2022)

Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumour activity as EGFR(wt)-TK inhibitor
por: Zhang, Yaling, et al.
Publicado: (2019)

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
por: Zhang, Qian, et al.
Publicado: (2020)

Towards safer anti-inflammatory therapy: synthesis of new thymol–pyrazole hybrids as dual COX-2/5-LOX inhibitors
por: El-Miligy, Mostafa M. M., et al.
Publicado: (2022)

A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship
por: Yadav, Tanuja T., et al.
Publicado: (2022)

Effective Tcl/Tk programming: writing better programs with Tcl and Tk
por: Harrison, Mark, et al.
Publicado: (1998)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
por: Fischer, Tim, et al.
Publicado: (2017)

Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents
por: Zhang, Yingqian, et al.
Publicado: (2023)

Albendazole repurposing on VEGFR-2 for possible anticancer application: In-silico analysis
por: Gaikwad, Nikita Maruti, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s6q9mm1tpda2p30h1g0hd2uvl7